Key facts
- This page summarizes Mohan Bala's Form 4 filing for Mersana Therapeutics, Inc. (MRSN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Jan 2025, 21:16.
Mohan Bala - 13 Jan 2025 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)
- Reporting relationship
- SVP, Chief Development Officer
- Issuer ticker
- MRSN
- Reported as of
- 13 Jan 2025
- Net transaction value
- -$2,147
- SEC form
- 4
- Accepted by SEC
- 15 Jan 2025, 21:16:15 UTC
- Prior SEC filing
- 29 Oct 2024
- Next SEC filing
- 17 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alejandra Carvajal, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mohan Bala filed Form 4 for Mersana Therapeutics, Inc. (MRSN) on 15 Jan 2025.
Change
- Previous filing in this sequence was filed on 29 Oct 2024.
- Current net transaction value: -$2,147.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRSN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +8,750
- Change %
- +16%
- Price
- $0.000000
- Shares after
- 63,481
- Date
- 13 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
MRSN
transaction
Common Stock
Sale
- Transaction value
- $2,147
- Shares
- -3,253
- Change %
- -5.1%
- Price
- $0.6600
- Shares after
- 60,228
- Date
- 14 Jan 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRSN
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -8,750
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 17,500
- Date
- 13 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,750
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023.
Footnote F2
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
Footnote F3
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
Footnote F4
25% of the total number of RSUs granted vested on January 13, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years.